Small-intestinal TG2-specific plasma cells at different stages of coeliac disease

Show full item record



Hietikko , M , Koskinen , O , Kurppa , K , Laurila , K , Saavalainen , P , Salmi , T , Ilus , T , Huhtala , H , Kaukinen , K & Lindfors , K 2018 , ' Small-intestinal TG2-specific plasma cells at different stages of coeliac disease ' , BMC Immunology , vol. 19 , 36 .

Title: Small-intestinal TG2-specific plasma cells at different stages of coeliac disease
Author: Hietikko, Minna; Koskinen, Outi; Kurppa, Kalle; Laurila, Kaija; Saavalainen, Päivi; Salmi, Teea; Ilus, Tuire; Huhtala, Heini; Kaukinen, Katri; Lindfors, Katri
Contributor organization: Immunomics
Immunobiology Research Program
Department of Medical and Clinical Genetics
Research Programs Unit
Date: 2018-12-06
Language: eng
Number of pages: 7
Belongs to series: BMC Immunology
ISSN: 1471-2237
Abstract: BackgroundIn coeliac disease, ingestion of gluten induces the production of transglutaminase 2 (TG2)-targeted autoantibodies by TG2-specific plasma cells present at high frequency in the small intestinal mucosa in untreated disease. During treatment with a gluten-free diet (GFD), the number of these cells decreases considerably. It has not been previously investigated whether the cells are also present prior to development of villous atrophy, or in non-responsive patients and those with dietary lapses. We aimed to define the frequency of small bowel mucosal TG2-specific plasma cells in coeliac disease patients with varying disease activity, and to investigate whether the frequency correlates with serum and small intestinal TG2-targeting antibodies as well as mucosal morphology and the number of intraepithelial lymphocytes.ResultsMucosal TG2-specific plasma cells were found in 79% of patients prior to development of mucosal damage, in all patients with villous atrophy, and in 63% of the patients after 1 year on GFD. In these disease stages, TG2-specific plasma cells accounted for median of 2.3, 4.3, and 0.7% of all mucosal plasma cells, respectively. After long-term treatment, the cells were present in 20% of the patients in clinical remission (median 0%) and in 60% of the patients with poor dietary adherence (median 5.8%). In patients with non-responsive coeliac disease despite strict GFD, the cells were found in only one (9%) subject; the cells accounted for 2.4% of all plasma cells. A positive correlation between the percentage of TG2-specific plasma cells and serum TG2 antibody levels (r(S)=0.69, P
Subject: Coeliac disease
Transglutaminase 2
Small intestine
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
s12865_018_0275_7.pdf 846.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record